Allen Annis - Aileron Therapeutics President
| ALRNDelisted Stock | USD 2.11 0.15 7.65% |
President
Dr. D. Allen Annis, Ph.D. is the Vice President Biophysical and Analytical Technologies of Aileron Therapeutics, Inc. He has served as our Senior Director of Biophysical and Analytical Technologies since November of 2007. He was previously Director of Technology Development at the ScheringPlough Research Institute in Cambridge, MA, and prior to that he was Vice President of New Technologies at NeoGenesis Pharmaceuticals, which was acquired by Schering in 2005. While at NeoGenesis, Dr. Annis codeveloped its core drug discovery platform, the affinity selectionmass spectrometrybased Automated Ligand Identification System . Dr. Annis authored several patents and publications that describe the ALIS technology, and invented many novel techniques that use ALIS to study proteindrug interactions since 2018.
| Age | 51 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 737 802 1989 |
| Web | https://www.aileronrx.com |
Aileron Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2586) % which means that it has lost $0.2586 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4432) %, meaning that it created substantial loss on money invested by shareholders. Aileron Therapeutics' management efficiency ratios could be used to measure how well Aileron Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Leslie Robbins | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 |
Aileron Therapeutics Leadership Team
Elected by the shareholders, the Aileron Therapeutics' board of directors comprises two types of representatives: Aileron Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aileron. The board's role is to monitor Aileron Therapeutics' management team and ensure that shareholders' interests are well served. Aileron Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aileron Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Garner, Principal Officer | ||
| Allen Annis, Vice President - Biophysical and Analytical Technologies | ||
| James Windsor, COO President | ||
| Brian Windsor, COO President |
Aileron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aileron Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 28.45 M | ||||
| Shares Outstanding | 21.67 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 28.47 % | ||||
| Number Of Shares Shorted | 141.21 K | ||||
| Price To Earning | (0.31) X | ||||
| Price To Book | 0.91 X | ||||
| Gross Profit | (17.01 M) |
Pair Trading with Aileron Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aileron Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aileron Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Aileron Stock
Moving against Aileron Stock
| 0.88 | DRTS | Alpha Tau Medical | PairCorr |
| 0.87 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.79 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.73 | VCYT | Veracyte Potential Growth | PairCorr |
| 0.66 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Aileron Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aileron Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aileron Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aileron Therapeutics to buy it.
The correlation of Aileron Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aileron Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aileron Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aileron Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Aileron Stock
If you are still planning to invest in Aileron Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aileron Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |